Fieldview Capital Management LLC Acquires New Position in TransMedics Group, Inc. $TMDX

Fieldview Capital Management LLC bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 15,291 shares of the company’s stock, valued at approximately $1,716,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Marshall Wace LLP grew its stake in shares of TransMedics Group by 258.7% in the second quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock worth $73,275,000 after acquiring an additional 394,340 shares in the last quarter. Zevenbergen Capital Investments LLC raised its stake in shares of TransMedics Group by 112.7% in the third quarter. Zevenbergen Capital Investments LLC now owns 258,523 shares of the company’s stock valued at $29,006,000 after acquiring an additional 136,995 shares in the last quarter. Next Century Growth Investors LLC purchased a new position in TransMedics Group in the second quarter valued at $16,049,000. Goldman Sachs Group Inc. boosted its holdings in TransMedics Group by 20.6% in the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock valued at $34,145,000 after purchasing an additional 86,721 shares during the period. Finally, Renaissance Group LLC acquired a new position in TransMedics Group during the 3rd quarter worth $8,536,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Performance

Shares of TMDX opened at $134.77 on Tuesday. The company’s 50 day simple moving average is $135.58 and its 200-day simple moving average is $127.08. The firm has a market cap of $4.62 billion, a PE ratio of 27.50 and a beta of 1.98. TransMedics Group, Inc. has a 12-month low of $62.23 and a 12-month high of $156.00. The company has a current ratio of 7.14, a quick ratio of 6.59 and a debt-to-equity ratio of 1.06.

Analysts Set New Price Targets

TMDX has been the topic of several recent research reports. Piper Sandler upped their price target on TransMedics Group from $140.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Oppenheimer lifted their price objective on TransMedics Group from $150.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Wall Street Zen lowered shares of TransMedics Group from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Stifel Nicolaus raised their target price on shares of TransMedics Group from $115.00 to $130.00 and gave the company a “hold” rating in a report on Monday. Finally, Canaccord Genuity Group boosted their price target on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Six research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $152.33.

Insider Buying and Selling

In other news, insider Anil P. Ranganath sold 864 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $139.12, for a total transaction of $120,199.68. Following the completion of the sale, the insider owned 13,091 shares in the company, valued at approximately $1,821,219.92. This represents a 6.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David Weill sold 3,571 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $146.82, for a total value of $524,294.22. Following the transaction, the director directly owned 12,134 shares in the company, valued at approximately $1,781,513.88. This represents a 22.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 16,205 shares of company stock valued at $2,353,002 in the last quarter. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.